XXXX and S  zary syndrome: survival and response to treatment.

@entity4888 @entity1 @entity66 @entity4889 @entity5 @entity784 @entity1778 @entity880 @entity1349
INTRODUCTION: @entity4888 ( @entity4888 ) is the most common variant of @entity784 . Although @entity4888 often has an indolent course, @entity1 can progress to, or present with, advanced stage (stage IIB-IVB) @entity4888 or with the @entity1778 ( @entity4889 ). @entity1 AND METHODS: We prospectively evaluated multiple prognostic variables, including demographics, age, TNMB (blood) stage, histologic features, @entity880 dehydrogenase (LDH), white blood cell counts, and response to treatment, in 168 @entity1 with @entity5 and @entity4889 from 2007 to June 2014. Kaplan-Meier estimates were used to determine the median @entity1349 ( @entity1349 ) and @entity66 ( @entity66 ). A Cox proportional hazards regression model was used to assess the prognostic factors with univariate and multivariate analyses. RESULTS: We analyzed 140 @entity1 with @entity4888 and 28 with @entity4889 , whose median survival was 2.47 years. A total of 79 @entity1 (47%) died of any cause. On univariate analysis, age, lymph node stage, and serum LDH level were significant for prognosis. On multivariate analysis, skin and node stage, age, large cell transformation, and LDH level were significantly associated with worse @entity1349 . Only N stage and LDH were significant for @entity66 . @entity1 who had received biologic response modifiers and histone deacetylase inhibitors first had better survival (2.5 years) than the @entity1 initially treated with multiagent chemotherapy (9 months). CONCLUSION: We found that only a few factors can predict @entity1349 and @entity66 for @entity1 with advanced @entity4888 / @entity4889 . Also, nonchemotherapy options should be preferred for front-line therapy to improve survival, outcomes, and side effects, including immunosuppression.
